SEARCH:   Advanced

Blood, 15 January 2005, Vol. 105, No. 2, pp. 728-734. Prepublished online as a Blood First Edition Paper on September 14, 2004; DOI 10.1182/blood-2004-07-2548. This Article Full Text (PDF) All Versions of this Article: 2004-07-2548v1 105/2/728    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Andersen, M. H. Articles by thor Straten, P. Search for Related Content PubMed PubMed Citation Articles by Andersen, M. H. Articles by thor Straten, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 7, 2004 Accepted August 29, 2004 Immunogenicity of Bcl-2 in cancer patients Mads Hald Andersen*, Inge Marie Svane, Pia Kvistborg, Ove J Nielsen, Eva Balslev, Sine Reker, Jurgen C Becker, and Per thor Straten Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark Department of Hematology, Herlev University Hospital, Copenhagen, Denmark Department of Hematology, State University Hospital, Copenhagen, Denmark Department of Dermatology, University of Wurzburg, Wurzburg, Germany * Corresponding author; email: mha{at}cancer.dk. Bcl-2 is a pivotal regulator of apoptotic cell death, and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design and Bcl-2 specific antisense oligonucleotides or small molecule Bcl-2 inhibitors have shown broad anti-cancer activities in pre-clinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of 'therapeutic' vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anti-cancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types, i.e., pancreatic cancer, breast cancer, AML and CLL. Additionally, we show that these Bcl-2 reactive T cells are indeed peptide specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies, e.g., in the combination with conventional radiation- and chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. B. Sorensen, R. S. Andersen, I. M. Svane, L. Engell-Noerregaard, S. R. Hadrup, E. Balslev, M. H. Andersen, and P. t. Straten CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53 Clin. Cancer Res., March 1, 2009; 15(5): 1543 - 1549. [Abstract] [Full Text] [PDF] J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells Clin. Cancer Res., November 15, 2008; 14(22): 7161 - 7166. [Abstract] [Full Text] [PDF] D. Zhai, C. Jin, C.-w. Shiau, S. Kitada, A. C. Satterthwait, and J. C. Reed Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins Mol. Cancer Ther., June 1, 2008; 7(6): 1639 - 1646. [Abstract] [Full Text] [PDF] M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood, February 1, 2008; 111(3): 1357 - 1365. [Abstract] [Full Text] [PDF] J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches Blood, December 15, 2006; 108(13): 4109 - 4117. [Abstract] [Full Text] [PDF] A. Anichini, R. Mortarini, L. Romagnoli, P. Baldassari, A. Cabras, C. Carlo-Stella, A. M. Gianni, and M. Di Nicola Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with {gamma}c cytokines Blood, January 15, 2006; 107(2): 602 - 609. [Abstract] [Full Text] [PDF] Z.-R. Yuan, R. Wang, J. Solomon, X. Luo, H. Sun, L. Zhang, and Y. Shi Identification and Characterization of Survival-Related Gene, a Novel Cell Survival Gene Controlling Apoptosis and Tumorigenesis Cancer Res., December 1, 2005; 65(23): 10716 - 10724. [Abstract] [Full Text] [PDF] S. Maia, W. N. Haining, S. Ansen, Z. Xia, S. A. Armstrong, N. P. Seth, P. Ghia, M. L. den Boer, R. Pieters, S. E. Sallan, et al. Gene Expression Profiling Identifies BAX-{delta} as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia Cancer Res., November 1, 2005; 65(21): 10050 - 10058. [Abstract] [Full Text] [PDF] J. C. Becker, P. thor Straten, and M. H. Andersen The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference? Cancer Res., April 1, 2005; 65(7): 2983 - 2983. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020